Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

Isabelle Borget,Anne Auperin,Jean-Pierre Pignon,Moncef Abbas,Olivier Bouché,Mireille Mousseau,Jean-Luc Raoul,Laurent Bedenne,Philippe Cassan,Marie-Christine Clavero-Fabri,Noël. Stremsdoerfer,Salvador Nasca,Anne-Marie Queuniet,Michel Ducreux

Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

2006

Isabelle Borget
Anne Auperin
Jean-Pierre Pignon
Moncef Abbas
Olivier Bouché
Mireille Mousseau
Jean-Luc Raoul
Laurent Bedenne
Philippe Cassan
Marie-Christine Clavero-Fabri
Noël. Stremsdoerfer
Salvador Nasca
Anne-Marie Queuniet
Michel Ducreux

Background: The De Gramont regimen (or high-dose LV5FU2, HD-LV5FU2) is considered a standard treatment for metastatic colorectal cancer. The aim of the study was to evaluate the eff

Keywords:

Pathology
Clinical trial
Folinic acid
Medicine
Cancer
Standard treatment
Colorectal cancer
Metastasis
Raltitrexed
Chemotherapy
Cost-effectiveness analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations